Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    February 2024
  1. LAINE C, Qaseem A, Moyer DV
    Putting Adult Vaccine Recommendations Into Action.
    Ann Intern Med. 2024 Feb 13. doi: 10.7326/M24-0242.
    PubMed    


  2. CENTOR RM, Tenforde MW, Dawood FS
    Web Exclusive. Annals On Call - Encouraging Influenza Vaccination.
    Ann Intern Med. 2024;177:eA230004.
    PubMed    


    January 2024
  3. ZERBO O, Bartlett J, Fireman B, Lewis N, et al
    Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-2023.
    PubMed     Abstract available


  4. WU Q, Tong J, Zhang B, Zhang D, et al
    Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
    Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
    PubMed     Abstract available


    November 2023
  5. TENFORDE MW, Dawood FS, Ellington SR, Grohskopf LA, et al
    Communicating the Value of Influenza Vaccines to Patients: Translating Vaccine Effectiveness to Acceptance.
    Ann Intern Med. 2023 Nov 28. doi: 10.7326/M23-2802.
    PubMed    


    September 2023
  6. KOTTON CN
    More Protection Against Respiratory Viral Infection: Respiratory Syncytial Virus Vaccines for Adults Aged 60 Years and Older.
    Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-2196.
    PubMed    


    June 2023

  7. Correction: Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/L23-0217.
    PubMed    


  8. AWAR M, Mylonakis E
    In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/J23-0039.
    PubMed     Abstract available


  9. AWAR M, Mylonakis E
    In older adults, an AS01(E)-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/J23-0038.
    PubMed     Abstract available


  10. BAJEMA KL, Berry K, Streja E, Rajeevan N, et al
    Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Ann Intern Med. 2023 Jun 6:M22-3565. doi: 10.7326/M22-3565.
    PubMed     Abstract available


    May 2023
  11. HULME WJ, Williamson E, Horne EMF, Green A, et al
    Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
    Ann Intern Med. 2023 May 2:M21-4269. doi: 10.7326/M21-4269.
    PubMed     Abstract available


    March 2023
  12. WANG TY, Wahed AS, Morris A, Kreuziger LB, et al
    Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
    Ann Intern Med. 2023 Mar 21. doi: 10.7326/M22-3350.
    PubMed     Abstract available


  13. WAN EYF, Yan VKC, Mok AHY, Wang B, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Ann Intern Med. 2023 Mar 14. doi: 10.7326/M22-3057.
    PubMed     Abstract available


    December 2022

  14. Correction: Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2022 Dec 27. doi: 10.7326/L22-0508.
    PubMed    


  15. DRYDEN-PETERSON S, Kim A, Kim AY, Caniglia EC, et al
    Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-2141.
    PubMed     Abstract available


    October 2022
  16. ROOZEN GVT, Prins MLM, van Binnendijk R, den Hartog G, et al
    Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
    Ann Intern Med. 2022 Oct 25. doi: 10.7326/M22-2089.
    PubMed    


  17. IOANNOU GN, Bohnert ASB, O'Hare AM, Boyko EJ, et al
    Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ann Intern Med. 2022 Oct 11. doi: 10.7326/M22-1856.
    PubMed     Abstract available


  18. GODDARD K, Hanson KE, Lewis N, Weintraub E, et al
    Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/M22-2274.
    PubMed    


    September 2022
  19. TAN CY, Chiew CJ, Lee VJ, Ong B, et al
    Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore.
    Ann Intern Med. 2022 Sep 13. doi: 10.7326/M22-2042.
    PubMed    


    August 2022
  20. BOTTON J, Jabagi MJ, Bertrand M, Baricault B, et al
    Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Ann Intern Med. 2022 Aug 23. doi: 10.7326/M22-0988.
    PubMed     Abstract available


  21. BROPHY JM
    mRNA COVID-19 vaccines were linked to myocarditis at 28 d (0.15 to 10 excess events/100 000 vaccinated persons).
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0057.
    PubMed     Abstract available


  22. AISENBERG GM
    In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0056.
    PubMed     Abstract available


    July 2022
  23. FORSTER D
    COVID-19 diagnosis, but not vaccination, was linked to increased risk for immune-mediated neurologic events.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0048.
    PubMed     Abstract available


  24. FOLLMANN D, Janes HE, Buhule OD, Zhou H, et al
    Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/M22-1300.
    PubMed     Abstract available


    May 2022
  25. ROSENBLUM HG, Lewis RM, Gargano JW, Querec TD, et al
    Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M21-3798.
    PubMed     Abstract available


  26. PERKINS RB, Saslow D, Oliver K
    Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-1309.
    PubMed    


  27. ASSOUMOU SA, Peterson A, Ginman E, James T, et al
    Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-0028.
    PubMed     Abstract available


  28. KRYCHTIUK KA, Newby LK
    Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons).
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0021.
    PubMed     Abstract available


  29. GRANWEHR BP
    In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at >/=7 d after the second dose.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0028.
    PubMed     Abstract available


  30. ZAHRADKA I, Petr V, Modos I, Magicova M, et al
    Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report.
    Ann Intern Med. 2022 May 3. doi: 10.7326/M21-2973.
    PubMed     Abstract available


    April 2022
  31. KOTTON CN
    Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/M22-1026.
    PubMed    


  32. ROTHBERG MB
    Community-Acquired Pneumonia.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/AITC202204190.
    PubMed     Abstract available


    March 2022
  33. ZHENG C, Duffy J, Liu IA, Sy LS, et al
    Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data.
    Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-3023.
    PubMed     Abstract available


  34. LARSON EB, Nelson JC
    In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barre syndrome.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0010.
    PubMed     Abstract available


  35. SILVESTRI EG, Borzak S
    In patients with MI or high-risk coronary disease, influenza vaccination reduced CV events at 12 mo.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0006.
    PubMed     Abstract available


    February 2022
  36. GAZIT S, Shlezinger R, Perez G, Lotan R, et al
    The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4130.
    PubMed     Abstract available


  37. HVIID A, Hansen JV, Thiesson EM, Wohlfahrt J, et al
    Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-2452.
    PubMed     Abstract available


  38. KANG M, Yi Y, Li Y, Sun L, et al
    Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-3509.
    PubMed     Abstract available


  39. CHANG R
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Another Way That Hospitalists Can Fight COVID-19.
    Ann Intern Med. 2022;175:HO2-HO3.
    PubMed    


    January 2022
  40. TSUN LAI FT, Li X, Peng K, Huang L, et al
    Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3700.
    PubMed     Abstract available


  41. QASEEM A, Yost J, Etxeandia-Ikobaltzeta I, Forciea MA, et al
    What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3272.
    PubMed     Abstract available


  42. SEE I, Lale A, Marquez P, Streiff MB, et al
    Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    Ann Intern Med. 2022 Jan 18. doi: 10.7326/M21-4502.
    PubMed     Abstract available


  43. CAILLARD S, Thaunat O, Benotmane I, Masset C, et al
    Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
    Ann Intern Med. 2022 Jan 11. doi: 10.7326/L21-0598.
    PubMed    


    December 2021
  44. IOANNOU GN, Locke ER, O'Hare AM, Bohnert ASB, et al
    COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3256.
    PubMed     Abstract available


  45. FAY MP, Hunsberger S, Follmann D
    Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3609.
    PubMed    


  46. ANAND S, Montez-Rath ME, Han J, Garcia P, et al
    SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4176.
    PubMed     Abstract available


  47. LAINE C, Moyer DV, Cotton D
    COVID-19: Challenging Clinical Questions.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4611.
    PubMed    



  48. Correction: Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021;174:1780.
    PubMed    


    November 2021
  49. KUMAR D, Ferreira VH, Hall VG, Hu Q, et al
    Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-3480.
    PubMed     Abstract available


  50. CHO BH, Weinbaum C, Tsai Y, Koppaka R, et al
    Influenza Vaccine Uptake and Missed Opportunities Among the Medicare-Covered Population With High-Risk Conditions During the 2018 to 2019 Influenza Season : A Retrospective Cohort Study.
    Ann Intern Med. 2021 Nov 16. doi: 10.7326/M21-1550.
    PubMed     Abstract available


  51. SARPATWARI A, Pandya A, Hyle EP, Persad G, et al
    COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/M21-3927.
    PubMed    


  52. UYEKI TM
    Influenza.
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/AITC202111160.
    PubMed     Abstract available


  53. MAKI DG
    Recommendations were made for diagnosis and management of allergic reactions to COVID-19 vaccines.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed     Abstract available


  54. GRANWEHR BP
    BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed     Abstract available


  55. SACKS HS
    The Novavax vaccine had 90% efficacy against COVID-19 >/=7 d after the second dose.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed     Abstract available


  56. DORFMAN AL, Murthy VL
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Myocarditis After Vaccination for SARS-CoV-2.
    Ann Intern Med. 2021;174:HO2-HO3.
    PubMed    


    October 2021
  57. HIMMELSTEIN J, Himmelstein DU, Woolhandler S, Dickman S, et al
    COVID-19-Related Care for Hispanic Elderly Adults With Limited English Proficiency.
    Ann Intern Med. 2021 Oct 26. doi: 10.7326/M21-2900.
    PubMed    


  58. NOVAZZI F, Taborelli S, Baj A, Focosi D, et al
    Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing.
    Ann Intern Med. 2021 Oct 19. doi: 10.7326/M21-3486.
    PubMed    


  59. MELMED GY, Botwin GJ, Sobhani K, Li D, et al
    Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-2483.
    PubMed    


  60. LAINE C, Cotton D, Moyer DV
    COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-3840.
    PubMed    


  61. DELANEY SW, Essien UR, Navathe A
    Disparate Impact: How Colorblind Policies Exacerbate Black-White Health Inequities.
    Ann Intern Med. 2021;174:1450-1451.
    PubMed    


    September 2021
  62. CURTIS JR, Cofield SS, Bridges SL Jr, Bassler J, et al
    The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
    Ann Intern Med. 2021 Sep 28. doi: 10.7326/M20-6928.
    PubMed     Abstract available


  63. REIF J, Heun-Johnson H, Tysinger B, Lakdawalla D, et al
    Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study.
    Ann Intern Med. 2021 Sep 21. doi: 10.7326/M21-2239.
    PubMed     Abstract available


  64. MOGHADAS SM, Sah P, Shoukat A, Meyers LA, et al
    Population Immunity Against COVID-19 in the United States.
    Ann Intern Med. 2021 Sep 14. doi: 10.7326/M21-2721.
    PubMed     Abstract available


    August 2021
  65. PALTIEL AD, Schwartz JL
    Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-2965.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.